Eczema Clinical Research Studies

Atopic dermatitis, or eczema, is the most common chronic inflammatory, pruritic skin disease. It causes intense itching and scratching which leads to a severe rash. Recent eczema studies have given researchers more information about this disease, which is leading to a better understanding of the ailment and new treatment options. There are currently a variety of eczema studies available at our center for patients with mild to severe atopic dermatitis. These studies include treatments such as biologics (complicated molecules that are manufactured within a living organism), a topical gel, and an oral medication designed to help decrease extremely itchy skin involved with eczema. These study medications are at the forefront of current medicine and are provided at absolutely no cost, and with no insurance needed. You may also be reimbursed for your time and travel and will receive care from a physician affiliated with the Clinical Research Center of Alabama.
For more information on any of the following eczema clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing [email protected]

BIOLOGIC INJECTION STUDY

Ages 19-55

ELI LILLY AD

The main purpose of this study is to learn whether an investigational drug (also known as the “study drug”) called lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo.

ORAL MEDICATION STUDY

Age 19+

Innovaderm

The main purpose of this study is to see if difelikeafalin oral tablets (taken by mouth) can reduce the intensity of itching and whether it is well tolerated in subjects with atopic dermatitis and moderate to severe pruritus. Atopic dermatitis is commonly known as eczema, pruritus is commonly known as itchy skin.

Investigational Topical Therapy

Age 2-5

Leo1181

The purpose of this trial is to find out if the delgocitinib cream is safe when used in adults, adolescents, and children. Delgocitinib is believed to interfere with the activity of an enzyme called Janus Kinase (JAK), which is involved in the immune response in your body.

Oral Medication

Age 19-70

Vanda

The purpose of this study is to evaluate the effect of an investigational drug called Tradipitant on symptoms associated with atopic dermatitis with atopic dermatitis and to assess the safety of Tradipitant.

Biologic Injection Study

Ages 19-75

MedImmune-AZ AD
The purpose of this study is to assess the effectiveness and safety of the study medication MEDI3506 compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults.

Biologic Injection Study

Ages 12+

Galderma AD
The purpose of this study is to assess the efficacy and safety of the study medication Nemolizumab in adolescent and adult patients with moderate to severe atopic dermatitis.

Biologic Injection Study

Ages 12+

Regeneron1924
The purpose of this study is to determine if the biologic medication, Dupixent, is effective in treating moderate-to-severe atopic hand and foot dermatitis that has been inadequately responsive to high potency topical steroids.

Become a Participant in our Eczema Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.